Brief: Ipsen Gains Global Rights For Development, Manufacturing Of SIM0613
22/12/2025 06:16
Dec 22 (Reuters) - Ipsen SA IPN.PA: IPSEN EXPANDS EARLY DEVELOPMENT PIPELINE WITH SIMCERE ZAIMING’S INNOVATIVE ANTIBODY DRUG CONJUGATE SIMCERE ZAIMING ELIGIBLE FOR UP TO $1.06B IN PAYMENTS SIM0613 TO ENTER PHASE I CLINICAL DEVELOPMENT IN H2 2026 TO HAVE MANUFACTURING RIGHTS FOR SIM0613 GAINS EXCLUSIVE GLOBAL RIGHTS, OUTSIDE OF GREATER CHINA, FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF SIM0613 Source text: ID:nGNE815xp0 Further company coverage: IPN.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients